ESC Heart Failure | Publication | Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort
Clinical features and dapagliflozin eligibility in a real‐world heart failure cohort. An example of the power of real-world data, technology, and collaboration to transform patient care.
Click below to read the study published in ESC Heart Failure.
The study aimed to shed light on patient eligibility for SGLT2 inhibitors as a therapy for heart failure patients, providing valuable information for clinicians and researchers.
AI and Natural Language Processing (NLP) was used to extract insights from anonymized EHRs, so as to complement the findings from clinical trials with results in a real-world clinical practice.
Reference: Beles, M, Masuy, I, Verstreken, S,Bartunek, J, Dierckx, R, Heggermont, W, Oeste, C, De Boeck, M, Fovel, I, Maris, M, Vermeulen, Z, Vanderheyden, M. Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort. ESC Heart Failure. 2023. https://doi.org/10.1002/ehf2.14381
The study aimed to shed light on patient eligibility for SGLT2 inhibitors as a therapy for heart failure patients, providing valuable information for clinicians and researchers.
AI and Natural Language Processing (NLP) was used to extract insights from anonymized EHRs, so as to complement the findings from clinical trials with results in a real-world clinical practice.
Reference: Beles, M, Masuy, I, Verstreken, S,Bartunek, J, Dierckx, R, Heggermont, W, Oeste, C, De Boeck, M, Fovel, I, Maris, M, Vermeulen, Z, Vanderheyden, M. Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort. ESC Heart Failure. 2023. https://doi.org/10.1002/ehf2.14381
